Shore Neal D
Medical Director, Carolina Urologic Research Center Myrtle Beach, SC.
Rev Urol. 2020;22(3):110-123.
With increasing treatment options available, the management of locally advanced and metastatic prostate cancer (PCa) is growing more complex, nuanced, and individualized. Strategies for combining surgery, radiation, chemotherapy, and androgen deprivation therapy (ADT) continue to evolve, as do ADT and immunotherapy options. Additionally, multiple adjunctive agents for metastatic PCa have been recently approved or are pending approval. As the number of locally advanced and metastatic prostate cancers being diagnosed rises, so does the need to consider patients' clinical situations and personal preferences. This review discusses current and potential future approaches to managing locally advanced and metastatic PCa.
随着可用治疗方案的增加,局部晚期和转移性前列腺癌(PCa)的管理变得越来越复杂、细致入微且个性化。手术、放疗、化疗和雄激素剥夺疗法(ADT)的联合策略不断发展,ADT和免疫疗法选项也是如此。此外,多种用于转移性PCa的辅助药物最近已获批准或正在等待批准。随着诊断出的局部晚期和转移性前列腺癌数量的增加,考虑患者临床情况和个人偏好的需求也在增加。本综述讨论了管理局部晚期和转移性PCa的当前及潜在未来方法。